Indivior (NASDAQ:INDV) Posts Earnings Results, Beats Expectations By $0.26 EPS

Indivior (NASDAQ:INDV) released its quarterly earnings results on Thursday. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.26, FiscalAI reports. The firm had revenue of $356.00 million for the quarter, compared to analysts’ expectations of $329.35 million. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.

Indivior Trading Up 1.6%

INDV stock traded up $0.57 during mid-day trading on Friday, reaching $35.82. The company’s stock had a trading volume of 1,023,534 shares, compared to its average volume of 2,219,040. The company’s 50 day moving average is $35.24 and its two-hundred day moving average is $35.62. The stock has a market cap of $4.23 billion, a PE ratio of 12.84 and a beta of 0.87. Indivior has a fifty-two week low of $27.68 and a fifty-two week high of $42.81.

Indivior Dividend Announcement

The firm also recently announced a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be issued a dividend of $8.13 per share.

Insider Activity

In other news, CAO Woodrow D. Anderson purchased 1,500 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was acquired at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the acquisition, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This represents a 5.74% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on INDV shares. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. Barclays raised their price objective on shares of Indivior from $43.00 to $45.00 and gave the stock an “overweight” rating in a research note on Wednesday. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Finally, Craig Hallum restated a “buy” rating and issued a $53.00 target price on shares of Indivior in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Indivior has an average rating of “Buy” and an average target price of $45.50.

About Indivior

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.